1187086-96-9

Basic information

• Product Name: N-[4-chloro-3-(trifluoromethyl)phenyl]-1H-imidazole-1-carboxamide
• Synonyms: N-[4-chloro-3-(trifluoromethyl)phenyl]-1H-imidazole-1-carboxamide
• CAS NO: 1187086-96-9
• Molecular Weight: 289.644
• Mol File: 1187086-96-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: N-[4-chloro-3-(trifluoromethyl)phenyl]-1H-imidazole-1-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[4-chloro-3-(trifluoromethyl)phenyl]-1H-imidazole-1-carboxamide(1187086-96-9)
• EPA Substance Registry System: N-[4-chloro-3-(trifluoromethyl)phenyl]-1H-imidazole-1-carboxamide(1187086-96-9)

Safety Data

• Hazardous Substances Data: 1187086-96-9(Hazardous Substances Data)

Upstream product

• 320-51-4 4-chloro-3-trifluoromethyl-aniline 
• 530-62-1 1,1'-carbonyldiimidazole 
• 288-32-4 1H-imidazole 
• 327-78-6 4-chloro-3-(trifluoromethyl)phenyl isocyanate 

Downstream Products

• 284461-73-0 sorafenib 
• 1547120-56-8 C₂₄H₁₈BrClF₃N₅O₂ 
• 1547120-51-3 C₂₄H₁₈Cl₂F₃N₅O₂ 
• 1547120-50-2 C₂₄H₁₈ClF₄N₅O₂ 
• 1547120-45-5 C₂₄H₁₉ClF₃N₅O₂ 
• 1130115-44-4 N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-(methyl-d₃)aminoformyl)-4-pyridyloxy)phenyl)urea 
• 1415661-97-0 3-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy)-N-hydroxybenzamide 
• 284462-98-2 methyl 3-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)phenoxy) benzoate 

Relevant articles and documents

Method for synthesizing sorafenib through solid ball milling

The invention relates to a method for synthesizing sorafenib through solid ball milling. The method comprises the following steps: taking a compound 4-(4-aminophenoxy)-N-methylpyridine-2-formamide anda compound 4-chlorine-3-trifluoromethyl isocyanate as raw materials, or taking a compound 4-chlorine-3-trifluoromethyl phenylamine, a compound N,N'-carbonyl diimidazole and a compound 4-(4-aminophenoxy)-N-methylpyridine-2-formamide as raw materials, and performing solid ball milling on the raw materials in a ball mill under the catalysis of a small amount of liquid (and alkali), so as to synthesize the sorafenib. The method has the main innovation points that the sorafenib is firstly synthesized in the ball mill through solid ball milling, and compared with the conventional method of synthesizing sorafenib in a liquid solvent, the method has the advantages of high reaction speed, not overflowed dust, good reaction controllability, high simpleness in operation, high reaction yield, small pollution and high feasibility.

DEUTERIUM-SUBSTITUTED OMEGA-DIPHENYLUREA AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE COMPOUNDS

This invention relates to deuterated ω-diphenylurea and derivatives and pharmaceutical acceptable salts thereof. And the pharmaceutical compositions comprising the pharmaceutically acceptable carrier and the deuterium-substituted ω-diphenylurea and derivatives and pharmaceutical acceptable salts thereof are also provided. The deuterium-substituted diphenylurea can be used in treatment or prevention of cancer and other related diseases.

Synthesis and antitumor activity of novel diaryl ether hydroxamic acids derivatives as potential HDAC inhibitors

A series of diaryl ether hydroxamic acids were synthesized for the first time and evaluated for the HDAC biology and antiproliferative activity. The structures of these new hydroxamic acids derivatives were confirmed by IR, 1H-NMR and mass spectrum. Some of these compounds showed micro molar activity in the HDAC inhibitory assay and against four cancer cell lines.